Altimmune, Inc. (ALT)
ALT moved a median of 0.00% 30 minutes after news, and -0.38% by the close. How ALT actually reacts to news — the realized, point-in-time move the market made, measured across 1,423 labeled events over the last three years with zero look-ahead.
ALT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 1,418 |
| 30-min | 0.00% | 48% | 1,419 |
| 60-min | -0.15% | 48% | 1,419 |
| to close | -0.38% | 45% | 1,394 |
| Middle 50% of ALT reactions | -1.06% to +1.18% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 1,423 |
Half of all Altimmune, Inc. news events land between -1.06% and +1.18% at 30 minutes.
Reaction stats as of 2026-08-31. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ALT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 22 | +0.77% | 68% | +0.23% |
| Rating reiterations | 55 | -0.23% | 29% | -0.80% |
Last 3 years, pulled 2026-08-31. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how ALT ranks against every other measured name →
That’s how ALT usually reacts — get an email when it moves on news →Email me when ALT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ALT's baseline. Nothing else.
Recent ALT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference | Press release | GlobeNewswire | -0.61% | -2.12% | |
| Altimmune Announces Second Quarter 2026 Financial Results and Business Update | Press release | GlobeNewswire | +1.15% | -3.93% | |
| Form 10-Q Altimmune, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.36% | -2.37% | |
| Form 8-K Altimmune, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +1.15% | -3.93% | |
| Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 | Press release | GlobeNewswire | +1.30% | -1.30% | |
| Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH | Press release | GlobeNewswire | -0.59% | +3.81% | |
| Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder | Press release | GlobeNewswire | -4.75% | -5.38% | |
| Form 8-K Altimmune, Inc. For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | -4.75% | -5.38% | |
| Form 8-K Altimmune, Inc. For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | -0.94% | -0.38% | |
| Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48-Week IMPACT Phase 2b Data Presented at EASL 2026 | Press release | GlobeNewswire | +1.65% | +1.15% | |
| Altimmune to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.50% | -0.33% | |
| New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026 | Press release | GlobeNewswire | -0.50% | -0.33% | |
| Altimmune Announces First Quarter 2026 Financial Results and Business Update | Press release | GlobeNewswire | -3.17% | +0.67% | |
| Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026 | Press release | GlobeNewswire | -3.17% | +0.67% | |
| Form 10-Q Altimmune, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.83% | -2.99% | |
| Form 8-K Altimmune, Inc. For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -3.17% | +0.67% | |
| Form S-8 Altimmune, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.83% | -2.99% | |
| Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 | Press release | GlobeNewswire | -0.16% | +6.54% | |
| Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities | Press release | GlobeNewswire | +0.00% | -1.41% | |
| Form 8-K Altimmune, Inc. For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.41% | |
| Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities | Press release | GlobeNewswire | +1.45% | -7.07% | |
| Altimmune Announces Proposed Underwritten Public Offering of Securities | Press release | GlobeNewswire | +1.45% | -7.07% | |
| Form S-3MEF Altimmune, Inc. | SEC filing · Form S-3MEF | SEC EDGAR | +1.45% | -7.07% | |
| Form 8-K Altimmune, Inc. For: Apr 16 | SEC filing · Form 8-K | SEC EDGAR | +1.10% | -1.41% | |
| Anti-Aging Protein Research Takes a Step Forward with Cell Cloning | Press release | PR Newswire | +0.15% | -2.99% | |
| Form ARS Altimmune, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.55% | -2.75% | |
| Form DEF 14A Altimmune, Inc. For: Apr 16 | SEC filing · Form DEF | SEC EDGAR | +0.55% | -2.75% | |
| Form 10-K Altimmune, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.26% | +0.00% | |
| Form PRE 14A Altimmune, Inc. For: Apr 16 | SEC filing · Form PRE | SEC EDGAR | -2.26% | +0.00% | |
| Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates | Press release | GlobeNewswire | -1.91% | -14.51% | |
| Form 8-K Altimmune, Inc. For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | -1.91% | -14.51% | |
| Altimmune to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.19% | -0.95% | |
| Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 | Press release | GlobeNewswire | -1.10% | -2.19% | |
| Form S-8 Altimmune, Inc. | SEC filing · Form S-8 | SEC EDGAR | -2.06% | -3.30% | |
| Form 8-K Altimmune, Inc. For: Feb 02 | SEC filing · Form 8-K | SEC EDGAR | -0.55% | -6.22% | |
| Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock | Press release | GlobeNewswire | +3.27% | +10.89% | |
| Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration | Press release | PR Newswire | -0.17% | -0.65% | |
| Form 8-K Altimmune, Inc. For: Jan 27 | SEC filing · Form 8-K | SEC EDGAR | +1.16% | -1.73% | |
| Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock | Press release | GlobeNewswire | -2.68% | -14.24% | |
| Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH | Press release | GlobeNewswire | +5.38% | +0.00% | |
| Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial | Press release | GlobeNewswire | -9.45% | -14.29% | |
| Form 8-K Altimmune, Inc. For: Dec 19 | SEC filing · Form 8-K | SEC EDGAR | -9.45% | -14.29% | |
| Form EFFECT Altimmune, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -0.37% | +4.86% | |
| Altimmune Announces CEO Transition and Succession Plan | Press release | GlobeNewswire | -1.99% | -2.38% | |
| Form 8-K Altimmune, Inc. For: Nov 30 | SEC filing · Form 8-K | SEC EDGAR | -1.99% | -2.38% | |
| Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference | Press release | GlobeNewswire | +2.64% | +1.17% | |
| Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025 | Press release | GlobeNewswire | -1.29% | +0.47% | |
| Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025 | Press release | GlobeNewswire | +1.77% | +4.32% | |
| Altimmune Announces Third Quarter 2025 Financial Results and Business Updates | Press release | GlobeNewswire | +1.71% | +3.68% | |
| Form 10-Q Altimmune, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.77% | +4.32% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ALT section they belong to.
Where else ALT is measured.
ALT earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| GENMARK DIAGNOSTICS (GNMK) | 1,451 | +0.06% | 51% |
| GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) | 1,448 | +0.01% | 51% |
| PerkinElmer, Inc. (PKI) | 1,409 | +0.11% | 56% |
| Zoetis Inc. Class A (ZTS) | 1,406 | +0.02% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Altimmune, Inc.'s median reaction calculated?
Every labeled ALT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,423 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of ALT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-31.
Does ALT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.